JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3014 BGJ398
1 Citation

Target: FGFR

Summary: FGFR inhibitor ,potent and selective

insoluble in H2O; insoluble in EtOH; ≥7 mg/mL
A4096 Belinostat (PXD101)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: Hydroxamate-type HDAC inhibitor

insoluble in H2O; ≥15.92 mg/mL
A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL
A8182 3-Deazaneplanocin A (DZNep) hydrochloride
1 Citation

Target: EZH2

Summary: SAHH and EZH2 inhibitor

insoluble in EtOH; ≥14.94 mg/mL
B3742 Thio-TEPA

Summary: alkylating agent used to treat cancer
B1858 Tranexamic Acid

Target: fibrinolysis

Summary: competitive inhibitor of plasminogen activation

insoluble in EtOH; insoluble in DMSO; ≥6.6 mg/mL
B2295 Pirarubicin
1 Citation

Target: Topoisomerases

Summary: Topoisomerase II inhibitor;anthracycline antibiotic

insoluble in H2O; insoluble in EtOH; ≥7.65 mg/mL
B1321 OTSSP167

Target: MELK

Summary: MELK inhibitor

insoluble in DMSO; insoluble in H2O; insoluble in EtOH
B1474 FT-207 (NSC 148958)

Summary: DNA/RNA synthesis inhibitor

≥100 mg/mL
A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL